BD reported revenue of $4.8 billion, a 1.5% increase as reported and 4.1% on a currency-neutral basis. The company raised its full-year base revenue guidance, enabling additional investments in growth and innovation while absorbing lower COVID-only diagnostic testing revenue and incremental FX impacts.
Revenue increased 1.5% as reported and 4.1% on a currency-neutral basis.
Base business revenue (excluding COVID-only diagnostic testing) grew 6.0% as reported, 8.7% currency-neutral.
GAAP and adjusted diluted EPS from continuing operations were $1.53 and $2.86, respectively.
The company raised full-year base revenue guidance, enabling additional investments in growth and innovation.
The company raised the lower-end and mid-point of its full-year revenue and adjusted EPS guidance ranges.
Visualization of income flow from segment revenue to net income